# AN2 Therapeutics, Inc.: financial statements, quarterly

ANTX · Nasdaq · CIK 1880438 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/antx.md) · [Financials](/companies/antx/financials.md) · [Filings](/companies/antx/filings.md) · [Insiders](/companies/antx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/antx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [14.4](/filings/0000950170-24-126282.md) | [14.9 d](/filings/0000950170-25-044366.md) | [14.7](/filings/0000950170-25-070358.md) | [12.1](/filings/0000950170-25-107301.md) | [8.3](/filings/0001193125-25-277673.md) | [5.4 d](/filings/0001193125-26-110693.md) | [7.7](/filings/0001193125-26-216755.md) | [3.2](/filings/0001193125-26-344569.md) | [7.0](/filings/0001193125-25-277673.md) | [6.9 d](/filings/0001193125-26-110693.md) | [6.7](/filings/0001193125-26-216755.md) | [6.0](/filings/0001193125-26-344569.md) |
| Operating income | $m | [(18.2)](/filings/0000950170-24-126282.md) | [(18.8) d](/filings/0000950170-25-044366.md) | [(18.3)](/filings/0000950170-25-070358.md) | [(15.9)](/filings/0000950170-25-107301.md) | [(14.0)](/filings/0001193125-25-277673.md) | [(8.6) d](/filings/0001193125-26-110693.md) | [(11.5)](/filings/0001193125-26-216755.md) | [(7.2)](/filings/0001193125-26-344569.md) | [(10.0)](/filings/0001193125-25-277673.md) | [(9.3) d](/filings/0001193125-26-110693.md) | [(10.6)](/filings/0001193125-26-216755.md) | [(8.9)](/filings/0001193125-26-344569.md) |
| Net income | $m | [(16.7)](/filings/0000950170-24-126282.md) | [(16.9) d](/filings/0000950170-25-044366.md) | [(16.6)](/filings/0001193125-25-277673.md) | [(14.4)](/filings/0001193125-25-277673.md) | [(12.7)](/filings/0001193125-25-277673.md) | [(7.5) d](/filings/0001193125-26-110693.md) | [(10.6)](/filings/0001193125-26-344569.md) | [(6.5)](/filings/0001193125-26-344569.md) | [(9.4)](/filings/0001193125-25-277673.md) | [(8.7) d](/filings/0001193125-26-110693.md) | [(10.0)](/filings/0001193125-26-344569.md) | [(8.2)](/filings/0001193125-26-344569.md) |
| Diluted EPS | $ per share | [(0.65)](/filings/0000950170-24-126282.md) | not reported | [(0.56)](/filings/0000950170-25-070358.md) | [(0.48)](/filings/0000950170-25-107301.md) | [(0.43)](/filings/0001193125-25-277673.md) | not reported | [(0.35)](/filings/0001193125-26-216755.md) | [(0.21)](/filings/0001193125-26-344569.md) | [(0.31)](/filings/0001193125-25-277673.md) | not reported | [(0.29)](/filings/0001193125-26-216755.md) | [(0.18)](/filings/0001193125-26-344569.md) |
| Basic EPS | $ per share | [(0.65)](/filings/0000950170-24-126282.md) | not reported | [(0.56)](/filings/0000950170-25-070358.md) | [(0.48)](/filings/0000950170-25-107301.md) | [(0.43)](/filings/0001193125-25-277673.md) | not reported | [(0.35)](/filings/0001193125-26-216755.md) | [(0.21)](/filings/0001193125-26-344569.md) | [(0.31)](/filings/0001193125-25-277673.md) | not reported | [(0.29)](/filings/0001193125-26-216755.md) | [(0.18)](/filings/0001193125-26-344569.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [32.6](/filings/0000950170-23-062081.md) | [15.6](/filings/0000950170-25-044366.md) | [24.7](/filings/0000950170-24-059556.md) | [26.8](/filings/0000950170-24-096243.md) | [33.5](/filings/0000950170-24-126282.md) | [21.4](/filings/0001193125-26-110693.md) | [20.0](/filings/0000950170-25-070358.md) | [18.2](/filings/0000950170-25-107301.md) | [18.0](/filings/0001193125-25-277673.md) | [19.9](/filings/0001193125-26-344569.md) | [53.5](/filings/0001193125-26-216755.md) | [44.3](/filings/0001193125-26-344569.md) |
| Current assets | $m | [126](/filings/0000950170-23-062081.md) | [111](/filings/0000950170-25-044366.md) | [116](/filings/0000950170-24-059556.md) | [107](/filings/0000950170-24-096243.md) | [97.7](/filings/0000950170-24-126282.md) | [86.3](/filings/0001193125-26-110693.md) | [69.6](/filings/0000950170-25-070358.md) | [67.5](/filings/0000950170-25-107301.md) | [64.0](/filings/0001193125-25-277673.md) | [59.9](/filings/0001193125-26-344569.md) | [87.5](/filings/0001193125-26-216755.md) | [80.0](/filings/0001193125-26-344569.md) |
| Total assets | $m | [154](/filings/0000950170-23-062081.md) | [139](/filings/0000950170-25-044366.md) | [121](/filings/0000950170-24-059556.md) | [108](/filings/0000950170-24-096243.md) | [97.7](/filings/0000950170-24-126282.md) | [92.1](/filings/0001193125-26-110693.md) | [81.3](/filings/0000950170-25-070358.md) | [75.8](/filings/0000950170-25-107301.md) | [67.2](/filings/0001193125-25-277673.md) | [62.0](/filings/0001193125-26-344569.md) | [87.5](/filings/0001193125-26-216755.md) | [81.7](/filings/0001193125-26-344569.md) |
| Current liabilities | $m | [14.8](/filings/0000950170-23-062081.md) | [14.0](/filings/0000950170-24-126282.md) | not reported | not reported | [10.0](/filings/0000950170-24-126282.md) | [10.2](/filings/0001193125-26-110693.md) | not reported | not reported | not reported | [8.7](/filings/0001193125-26-344569.md) | [5.6](/filings/0001193125-26-216755.md) | [5.6](/filings/0001193125-26-344569.md) |
| Total liabilities | $m | [14.8](/filings/0000950170-23-062081.md) | [14.0](/filings/0000950170-25-044366.md) | [10.7](/filings/0000950170-24-059556.md) | [10.1](/filings/0000950170-24-096243.md) | [10.0](/filings/0000950170-24-126282.md) | [10.2](/filings/0001193125-26-110693.md) | [8.0](/filings/0000950170-25-070358.md) | [7.0](/filings/0000950170-25-107301.md) | [6.9](/filings/0001193125-25-277673.md) | [8.9](/filings/0001193125-26-344569.md) | [5.7](/filings/0001193125-26-216755.md) | [5.8](/filings/0001193125-26-344569.md) |
| Shareholders' equity | $m | [139](/filings/0000950170-24-126282.md) | [125](/filings/0001193125-26-110693.md) | [111](/filings/0001193125-25-277673.md) | [98.4](/filings/0001193125-25-277673.md) | [87.7](/filings/0001193125-25-277673.md) | [81.8](/filings/0001193125-26-344569.md) | [73.3](/filings/0001193125-26-344569.md) | [68.8](/filings/0001193125-26-344569.md) | [60.4](/filings/0001193125-25-277673.md) | [53.1](/filings/0001193125-26-344569.md) | [81.8](/filings/0001193125-26-344569.md) | [75.9](/filings/0001193125-26-344569.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(11.8) d](/filings/0000950170-24-126282.md) | [(17.1) d](/filings/0000950170-25-044366.md) | [(17.6)](/filings/0000950170-25-070358.md) | [(14.4) d](/filings/0000950170-25-107301.md) | [(12.0) d](/filings/0001193125-25-277673.md) | [(5.3) d](/filings/0001193125-26-110693.md) | [(10.6)](/filings/0001193125-26-216755.md) | [(7.6) d](/filings/0001193125-26-344569.md) | [(6.4) d](/filings/0001193125-25-277673.md) | [(5.2) d](/filings/0001193125-26-110693.md) | [(12.1)](/filings/0001193125-26-216755.md) | [(7.0) d](/filings/0001193125-26-344569.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [19.3](/filings/0000950170-23-062081.md) | [19.4](/filings/0000950170-24-059556.md) | [19.5](/filings/0000950170-24-096243.md) | [25.6](/filings/0000950170-24-126282.md) | [29.8](/filings/0000950170-25-070358.md) | [29.8](/filings/0000950170-25-107301.md) | [29.8](/filings/0001193125-25-277673.md) | [30.1](/filings/0001193125-26-216755.md) | [30.2](/filings/0001193125-26-344569.md) | [30.3](/filings/0001193125-25-277673.md) | [34.1](/filings/0001193125-26-216755.md) | [44.8](/filings/0001193125-26-344569.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 37,736,237 at 2026-08-06, from the cover of the [10-Q filed 2026-08-11](/filings/0001193125-26-344569.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.